Which manufacturer is Sotoracib (AMG 510) produced by and its quality supervision status?

Sotorasib (AMG 510, trade name Sotorasib) is an oral small molecule targeted drug specifically targeting KRAS G12C mutations. It is developed and produced by the American company Amgen. AmgenAs a world-renowned biopharmaceutical company, it has strict drug research and development, production and quality control systems to ensure that each batch of drugs meets international pharmacopoeia standards and regulatory requirements. The launch of sotorasiib is not only based on data from multiple international clinical trials, but has also undergone strict approval by regulatory agencies such as FDA and EMA to ensure the safety and effectiveness of the drug.

In the production process, Amgen the company strictly implements GMP (Good Manufacturing Practice) standards and has a complete quality management system from raw material procurement, process control to finished product inspection. The purity and content of the active ingredients of the drug have been tested with high precision to ensure that each tablet of Sotorasib meets the specifications. In addition, the company also strictly monitors the production environment, including air cleanliness, temperature and humidity control, and cross-contamination prevention and control, to maximize the quality and safety of pharmaceuticals.

In terms of quality supervision, sotoracib is not only subject to strict internal control within the company during the production process, but is also subject to continuous supervision by drug regulatory agencies in various countries. After a drug is put on the market, regulatory agencies will require companies to conduct adverse drug reaction monitoring and risk management plans (RMP) to promptly discover and respond to possible drug safety issues. This regulatory system effectively ensures the safety and consistency of sotoraxib in clinical use, and also provides patients with reliable medication protection.

In addition, for overseas generic drugs and versions sold in various regions, Amgen and local regulatory agencies strictly control their production, circulation and quality. Although there are more affordable generic drugs in some overseas markets, their drug ingredients are basically the same as the original drugs, and they must also comply with local GMP and pharmacopoeia standards. Overall, whether it is the original drug or a regulated generic version, the production and quality management system of sotoraxib reflects high standards of drug safety and clinical controllability, providing a reliable treatment option for patients with KRAS G12C mutation-positive tumors.

Reference link: https://www.drugs.com